vs
爵士制药（JAZZ）与罗布乐思（RBLX）财务数据对比。点击上方公司名可切换其他公司
罗布乐思的季度营收约是爵士制药的1.2倍（$1.4B vs $1.2B），爵士制药净利率更高（17.0% vs -22.3%，领先39.3%），罗布乐思同比增速更快（43.2% vs 10.1%），爵士制药自由现金流更多（$345.8M vs $308.6M），过去两年罗布乐思的营收复合增速更高（32.9% vs 15.2%）
爵士制药是一家全球性生物制药企业，核心业务聚焦肿瘤学与神经科学两大领域，2003年在美国加利福尼亚州成立，当前总部坐落于爱尔兰首都都柏林。
罗布乐思（Roblox Corporation）是总部位于美国加利福尼亚州圣马特奥的游戏企业，由大卫·巴斯祖奇与埃里克·卡塞尔于2004年共同创立。公司核心产品为同名线上游戏创作平台Roblox，于2006年正式上线，截至2024年12月底全球员工规模已超2400人。
JAZZ vs RBLX — 直观对比
营收规模更大
RBLX
是对方的1.2倍
$1.2B
营收增速更快
RBLX
高出33.1%
10.1%
净利率更高
JAZZ
高出39.3%
-22.3%
自由现金流更多
JAZZ
多$37.2M
$308.6M
两年增速更快
RBLX
近两年复合增速
15.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.2B | $1.4B |
| 净利润 | $203.5M | $-316.0M |
| 毛利率 | — | 77.7% |
| 营业利润率 | 21.2% | -25.3% |
| 净利率 | 17.0% | -22.3% |
| 营收同比 | 10.1% | 43.2% |
| 净利润同比 | 6.5% | -43.9% |
| 每股收益（稀释后） | $3.34 | $-0.44 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收JAZZRBLX
| Q4 25 | $1.2B | $1.4B | ||
| Q3 25 | $1.1B | $1.4B | ||
| Q2 25 | $1.0B | $1.1B | ||
| Q1 25 | $897.8M | $1.0B | ||
| Q4 24 | $1.1B | $988.2M | ||
| Q3 24 | $1.1B | $919.0M | ||
| Q2 24 | $1.0B | $893.5M | ||
| Q1 24 | $902.0M | $801.3M |
净利润JAZZRBLX
| Q4 25 | $203.5M | $-316.0M | ||
| Q3 25 | $251.4M | $-255.6M | ||
| Q2 25 | $-718.5M | $-278.4M | ||
| Q1 25 | $-92.5M | $-215.1M | ||
| Q4 24 | $191.1M | $-219.6M | ||
| Q3 24 | $215.1M | $-239.3M | ||
| Q2 24 | $168.6M | $-205.9M | ||
| Q1 24 | $-14.6M | $-270.6M |
毛利率JAZZRBLX
| Q4 25 | — | 77.7% | ||
| Q3 25 | — | 78.2% | ||
| Q2 25 | — | 78.2% | ||
| Q1 25 | — | 78.3% | ||
| Q4 24 | — | 77.9% | ||
| Q3 24 | — | 77.7% | ||
| Q2 24 | — | 77.8% | ||
| Q1 24 | — | 77.7% |
营业利润率JAZZRBLX
| Q4 25 | 21.2% | -25.3% | ||
| Q3 25 | 5.1% | -21.8% | ||
| Q2 25 | -65.6% | -29.8% | ||
| Q1 25 | -6.2% | -24.6% | ||
| Q4 24 | 17.5% | -24.7% | ||
| Q3 24 | 24.7% | -30.4% | ||
| Q2 24 | 19.5% | -26.6% | ||
| Q1 24 | 7.3% | -37.7% |
净利率JAZZRBLX
| Q4 25 | 17.0% | -22.3% | ||
| Q3 25 | 22.3% | -18.8% | ||
| Q2 25 | -68.7% | -25.8% | ||
| Q1 25 | -10.3% | -20.8% | ||
| Q4 24 | 17.6% | -22.2% | ||
| Q3 24 | 20.4% | -26.0% | ||
| Q2 24 | 16.5% | -23.0% | ||
| Q1 24 | -1.6% | -33.8% |
每股收益（稀释后）JAZZRBLX
| Q4 25 | $3.34 | $-0.44 | ||
| Q3 25 | $4.08 | $-0.37 | ||
| Q2 25 | $-11.74 | $-0.41 | ||
| Q1 25 | $-1.52 | $-0.32 | ||
| Q4 24 | $2.97 | $-0.32 | ||
| Q3 24 | $3.42 | $-0.37 | ||
| Q2 24 | $2.49 | $-0.32 | ||
| Q1 24 | $-0.23 | $-0.43 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.4B | $3.1B |
| 总债务越低越好 | $5.4B | $1.2B |
| 股东权益账面价值 | $4.3B | $394.5M |
| 总资产 | $11.7B | $9.6B |
| 负债/权益比越低杠杆越低 | 1.24× | 2.98× |
8季度趋势，按日历期对齐
现金及短期投资JAZZRBLX
| Q4 25 | $1.4B | $3.1B | ||
| Q3 25 | $1.3B | $2.9B | ||
| Q2 25 | $1.2B | $2.6B | ||
| Q1 25 | $1.9B | $2.7B | ||
| Q4 24 | $2.4B | $2.4B | ||
| Q3 24 | $2.2B | $2.3B | ||
| Q2 24 | $1.4B | $2.4B | ||
| Q1 24 | $1.4B | $2.4B |
总债务JAZZRBLX
| Q4 25 | $5.4B | $1.2B | ||
| Q3 25 | $5.4B | — | ||
| Q2 25 | $5.4B | — | ||
| Q1 25 | $5.4B | — | ||
| Q4 24 | $6.1B | $1.2B | ||
| Q3 24 | $6.1B | — | ||
| Q2 24 | $5.7B | — | ||
| Q1 24 | $5.7B | — |
股东权益JAZZRBLX
| Q4 25 | $4.3B | $394.5M | ||
| Q3 25 | $4.0B | $407.6M | ||
| Q2 25 | $3.7B | $353.2M | ||
| Q1 25 | $4.2B | $310.7M | ||
| Q4 24 | $4.1B | $221.4M | ||
| Q3 24 | $4.2B | $189.9M | ||
| Q2 24 | $3.8B | $121.5M | ||
| Q1 24 | $3.7B | $71.6M |
总资产JAZZRBLX
| Q4 25 | $11.7B | $9.6B | ||
| Q3 25 | $11.4B | $8.6B | ||
| Q2 25 | $10.9B | $7.8B | ||
| Q1 25 | $11.5B | $7.5B | ||
| Q4 24 | $12.0B | $7.2B | ||
| Q3 24 | $12.3B | $6.7B | ||
| Q2 24 | $11.4B | $6.5B | ||
| Q1 24 | $11.3B | $6.3B |
负债/权益比JAZZRBLX
| Q4 25 | 1.24× | 2.98× | ||
| Q3 25 | 1.35× | — | ||
| Q2 25 | 1.45× | — | ||
| Q1 25 | 1.29× | — | ||
| Q4 24 | 1.49× | 5.48× | ||
| Q3 24 | 1.47× | — | ||
| Q2 24 | 1.52× | — | ||
| Q1 24 | 1.54× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $362.5M | $607.0M |
| 自由现金流经营现金流 - 资本支出 | $345.8M | $308.6M |
| 自由现金流率自由现金流/营收 | 28.9% | 21.8% |
| 资本支出强度资本支出/营收 | 1.4% | 21.1% |
| 现金转化率经营现金流/净利润 | 1.78× | — |
| 过去12个月自由现金流最近4个季度 | $1.3B | $1.4B |
8季度趋势，按日历期对齐
经营现金流JAZZRBLX
| Q4 25 | $362.5M | $607.0M | ||
| Q3 25 | $474.6M | $546.2M | ||
| Q2 25 | $88.9M | $199.3M | ||
| Q1 25 | $429.8M | $443.9M | ||
| Q4 24 | $398.6M | $184.5M | ||
| Q3 24 | $398.7M | $247.4M | ||
| Q2 24 | $331.4M | $151.4M | ||
| Q1 24 | $267.2M | $238.9M |
自由现金流JAZZRBLX
| Q4 25 | $345.8M | $308.6M | ||
| Q3 25 | $459.4M | $443.6M | ||
| Q2 25 | $75.9M | $176.7M | ||
| Q1 25 | $415.9M | $426.5M | ||
| Q4 24 | $385.3M | $120.6M | ||
| Q3 24 | $388.0M | $218.0M | ||
| Q2 24 | $324.3M | $111.7M | ||
| Q1 24 | $260.3M | $192.3M |
自由现金流率JAZZRBLX
| Q4 25 | 28.9% | 21.8% | ||
| Q3 25 | 40.8% | 32.6% | ||
| Q2 25 | 7.3% | 16.3% | ||
| Q1 25 | 46.3% | 41.2% | ||
| Q4 24 | 35.4% | 12.2% | ||
| Q3 24 | 36.8% | 23.7% | ||
| Q2 24 | 31.7% | 12.5% | ||
| Q1 24 | 28.9% | 24.0% |
资本支出强度JAZZRBLX
| Q4 25 | 1.4% | 21.1% | ||
| Q3 25 | 1.3% | 7.5% | ||
| Q2 25 | 1.2% | 2.1% | ||
| Q1 25 | 1.5% | 1.7% | ||
| Q4 24 | 1.2% | 6.5% | ||
| Q3 24 | 1.0% | 3.2% | ||
| Q2 24 | 0.7% | 4.4% | ||
| Q1 24 | 0.8% | 5.8% |
现金转化率JAZZRBLX
| Q4 25 | 1.78× | — | ||
| Q3 25 | 1.89× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 2.09× | — | ||
| Q3 24 | 1.85× | — | ||
| Q2 24 | 1.97× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
JAZZ
| Xywav | $465.5M | 39% |
| Total Oncology | $337.8M | 28% |
| Rylaze Enrylaze | $108.2M | 9% |
| Zepzelca | $90.4M | 8% |
| Product And Services Royalties And Contract Revenue | $65.5M | 5% |
| High Sodium AG Oxybate Product Royalty Revenue | $55.7M | 5% |
| Xyrem | $37.8M | 3% |
| Vyxeos | $34.7M | 3% |
| Ziihera | $8.5M | 1% |
| Other Products | $2.8M | 0% |
| Sativex | $1.5M | 0% |
RBLX
暂无分部数据
